E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
The medical condition under investigation is complete androgen insensitivity syndrome (CAIS) in gonadectomized patients with 46,XY karyotype due to mutations of the androgen receptor, which lead to loss of function of androgens. |
|
E.1.1.1 | Medical condition in easily understood language |
Complete androgen insensitivity syndrome (CAIS) in gonadectomized patients with normale male chromosome set due to mutations of the androgen receptor and subsequent to loss of function of androgens. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10056292 |
E.1.2 | Term | Androgen insensitivity syndrome |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Detection of differences in the effects of testosterone versus estradiol treatment on general quality of life measured by psychological sum scale of the SF-36 questionnaire |
|
E.2.2 | Secondary objectives of the trial |
Comparison of levels and excretion products of testosterone, estradiol and other metabolites of sexual hormones
Analysis of effects of different levels of hormones on the levels of SHBG, LH, FSH, Insulin, Glucose, Cholesterol (total, HDL, LDL), Triglycerides, Hematocrit and Hemoglobin
Detection of differences in the effects of testosterone versus estradiol treatment on general and sexual quality of life
Analysis of residual androgen receptor activity and correlation between residual activity and effects of testosteron
Comparison of the incidence of adverse events between both treatments
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Postpubertal adult patients (age >= 18 and <= 55 years) with complete androgen insensitivity syndrome with 46, XY karyotype classified as either Sinnecker Type 5A or 5B
Mutation of the androgen receptor gene proved
Gonadectomy at least 1 year before entering the study
Informed consent to participate in the study |
|
E.4 | Principal exclusion criteria |
Disorder of sex developement other than complete androgen insensitivity syndrome
Steroid medication other than study medication (exception: steroids for inhalation, short-term administration of other steroids)
Gonads in situ
Disorder of liver function
Chronic skin disease with influence on resorption of the gels
Serious chronic disorders affected by sex steroid medication
Malignant disorders (exception: cured malignant disorders which are not dependent on hormones)
Severe psychiatric disorder
Porphyria
Previous idiopathic or present venous thrombotic or embolic events
Present or recent arterial thrombotic or embolic events (e.g. myocardial infarction or angina pectoris)
Allergy to study medication or excipients in study medication
Clinical trial therapy outside of this trial during or within 4 weeks of study treatment |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Quality of life as measured by the psychlogical sum scale of the SF-36 questionnaire |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At months 0, 2 (start of study medication 1), 5, 8 (end of study medication 1 and start of study medication 2), 11, 14 (end of study medikation 2) and 17 (end of study). |
|
E.5.2 | Secondary end point(s) |
Quality of life as measured by the physical sum scale of the SF-36 questionnaire
Psychological well-being assessed by the questionnaire Brief Symptom Inventory
Sexual quality of life as measured by the questionnaire FSFI-d
Hormone levels in serum and urine, SHBG, LH, FSH, Insulin, Glucose, Cholesterol (total, HDL, LDL), Triglycerides, Hematocrit and Hemoglobin
Adverse events |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
At months 0, 2 (start of study medication 1), 5, 8 (end of study medication 1 and start of study medication 2), 11, 14 (end of study medikation 2) and 17 (end of study). |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 11 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 11 |
E.8.9.2 | In all countries concerned by the trial days | 0 |